Wang B, et al. Detection of clinically significant prostate cancer by micro-ultrasound-informed systematic biopsy during MRI/micro-ultrasound fusion biopsy

APPENDIX

Supplementary Table 1. Cancer detection by core for micro-ultrasound in targeted biopsies			
	# of cores taken	Any cancer detected (% of total)	Grade group ≥2 cancer detected (% of total)
Overall	204	110 (54%)	58 (28%)
PRI-MUS score ≤2 3 4 5	27 72 57 48	9 (33%) 40 (56%) 30 (53%) 31 (65%)	5 (19%) 22 (31%) 13 (23%) 18 (38%)

PRI-MUS: Prostate Risk Identification using Micro-Ultrasound.

Supplementary Table 2. Clinically significant cancer detection by core type			
Patients with csPCa	n=39		
Diagnosed on targeted biopsy only, n (%)	3 (8%)		
Diagnosed on targeted + systematic biopsies, n (%)	21 (54%)		
Diagnosed on systematic biopsy only, n (%) PRI-MUS score <pre></pre>	15 (38%) 0 1		
5	5		

csPCa: clinically significant prostate cancer; PRI-MUS: Prostate Risk Identification using Micro-Ultrasound.